"In vitro, the potency of LGD-2226 was similar to that of DHT in an androgen-responsive luciferase reporter assay. In prostate cancer cells, LGD-2226 showed weak partial agonism in activation of the prostate-specific antigen (PSA) promoter [185]. LGD-2226 is reportedly in phase I clinical development [28], but a recent publication suggests that the development of this compound has been abandoned because of preclinical toxicity issues [29]."
Unfortunately I don't have a reference for it. Bold and coloring are added by me.